FDA Drug recall D-0085-2023
Oxcarbazepine Tablets 600mg, packaged in a) 100- count bottles (NDC 62756-185-88), b) 500-count bottles (NDC 62756-185-13), c)1000-count bo…
- FDA Drug
- Class II
- terminated
- Published 2022-12-28
On 2022-12-28 the FDA classified a Class II recall of Oxcarbazepine Tablets 600mg, packaged in a) 100- count bottles (NDC 62756-185-88), b) 500-count bottles (NDC 62756-185-13), c)1000-count bo… by Sun Pharmaceutical Industries, citing presence of foreign substance.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0085-2023 |
| Classification | Class II |
| Status | terminated |
| Initiated | 2022-12-01 |
| Published | 2022-12-28 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Sun Pharmaceutical Industries |
| Distribution | US |
Product
Oxcarbazepine Tablets 600mg, packaged in a) 100- count bottles (NDC 62756-185-88), b) 500-count bottles (NDC 62756-185-13), c)1000-count bottles (NDC 62756-185-18), Rx Only, Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Industries Limited Halol-Baroda Highway, Halol-389 350, Gujarat, India.
Reason
Presence of foreign substance
Identifiers
| ndc | 62756-183-83 |
|---|---|
| ndc | 62756-183-88 |
| ndc | 62756-183-08 |
| ndc | 62756-183-13 |
| ndc | 62756-183-18 |
| ndc | 62756-184-83 |
| ndc | 62756-184-88 |
| ndc | 62756-184-08 |
| ndc | 62756-184-13 |
| ndc | 62756-184-18 |
| ndc | 62756-185-83 |
| ndc | 62756-185-88 |
| ndc | 62756-185-08 |
| ndc | 62756-185-13 |
| ndc | 62756-185-18 |
| code_info | a) Lot HAC1474A, Expires 03/2023 b) Lot HAC1503A, Expires 03/2023 c) Lot HAC1474B, Expires 03/2023 |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0085-2023%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.